Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Market systems can be volatile. I've always prefered the term "order imbalance" versus "manipulation".
Some of us are adept at reading these imbalances and become successful traders, others not so much.
I retired early too thanks to being able to read market patterns.
That will be awesome.
$AVXL unfortunately plants is own seeds of FUD by creating uncertainty and doubt with it's readouts.
$12.05 was the close not $11.77, so $12 assignment was just normal.
You were assigned on your $12 out of the money covered call write? That is odd.
Creditors will decide what to do with the "assets" as bankruptcy is not an option for marijuana companies and common equity is worthless.
Current assets = 7.21 million and current liabilities = 75.0 million
Assets = 54 million and liabilities = 96 million
My guess is all operations will cease and the company will be dissolved. The remaining assets will be transferred to a new corporate entity owned by the creditors.
$AVXL follows good accounting principles and has never received a warning letter. How does your non sequitur about the SEC apply to Anavex planning of the FXS trial?
If the FDA was faster in granting Fragile X Orphan Drug Status the trial would have already been in progress.
https://www.anavex.com/post/us-fda-orphan-drug-designation-to-anavex-2-73-blarcamesine-for-the-treatment-of-fragile-x-syndrome
I'll take good planning over hasty actions any day.
A Top Line Readout required zero analysis from Ariana.
I assure you there will be multiple subgroup analytics from the AD 2b/3 trial.
Thanks for inserting the FUD lately it helps accumulators like myself.
My biotech track record was worse, yet the few I predicted correctly enabled me to retire early.
Taking calculated risk has always been one of my "mantra's"
Novel approaches such as Sigma 1R modulation is an "idea with no precedence."
Watch or listen to any recent presentation as each indication has mRNA and indication specific biomarkers of response.
Accelerated Approval and surrogate/biological biomarkers is actually part of the plan if one has been paying attention to Anavex's analytical partner Ariana Pharma presentations.
https://www.arianapharma.com/
The exact flow of shares from the Deep Rock transaction is not known and cannot be discerned by institutional holding reports.
Deep Rock may have simply acted as a middle man for other investors which why Deep Rock as an entity never showed up as a holder on the institutional report. The shares were distributed to other persons or entities soon after the transaction was complete.
https://www.anavex.com/post/anavex-life-sciences-announces-50-million-registered-direct-offering-1
That's why the upcoming PDD Open Label Extension data is needed.
I'm of the opinion once the PDD OLE data analysis is presented the Michael J Fox Foundation funded PD imaging trial will be started.
Not sure, do you? I'm also waiting for data too as I know some trial patients were actually Lewy Body Dementia not PDD.
So I'm of the opinion AD, PDD, and Lewy Body Dementia will be among the dementias covered by 2-73.
I'm ahead of the curve on LBD, but as also an alpha synuclein related disease, I'm hopeful it to will be a treatable indication too.
We are waiting for quite a few items on PDD.
I was simply pointing out that a CEO stating a has been made is not the same as a CEO stating a trial will be published.
Maybe I need to be more through in my responses to not confuse people as
I made a direct quote LOL! No recall needed.
"ANAVEX®2-73-PDD-001 study results will be SUBMITTED for publication in a peer-reviewed medical journal." is also often used. For example:
https://www.anavex.com/post/anavex-life-sciences-presents-proof-of-concept-controlled-phase-2-clinical-trial-data
"ANAVEX®2-73-PDD-001 study results will be SUBMITTED for publication in a peer-reviewed medical journal." is also often used. For example:
https://www.anavex.com/post/anavex-life-sciences-presents-proof-of-concept-controlled-phase-2-clinical-trial-data
Submitted for publication is what Anavex stated, not will be published.
Ah gracias! I am technically retired and don't follow things a closely. I see there was a rule change in 2020.
https://www.sec.gov/corpfin/secg-accelerated-filer-and-large-accelerated-filer-definitions
Haven't read the details but the exemptions to the rule for Smaller Reporting Companies to be Non-Accelerated Filers no longer applies to $AVXL once it crossed over $700 million or more in public float.
Not too much of a stretch for a "fly on the wall" to guess $AVXL has been seeking investment banking advice.
It will be interesting what tier level of firm wins the business and how the deal structured.
We know the rare disease franchise will remain "in-house". but AD/dementia is open for discussion.
ZERO need for any extensions...so lets nip that in the bud..
$AVXL on average files mid December. Except last year when they filed on 11/24/2021.
Yes any activity after the reporting quarters end will be in the subsequent events section.
https://www.sec.gov/edgar/browse/?CIK=1314052&owner=exclude
My favorite phrase, that is still in the compliance rules of the industry is the use of the term "timely disclosure" ... WTF does that mean? It all depended on how nice the auditor was at the time and the subjective seriousness if the internal item being reviewed.
To which I say "no duh" ...
"He has no intention of further dilution" I agree, but situations change and smart CEO's utilize equity in many different ways.
BTW, I never said $AVXL was going to the market for more cash, I simply gave my counter opinion to Investor2014's comments as to when I thought it could be a prudent time where a microcap biotech might raise funds.
I've been on the fringes of the investment banking public and private a long time and "intentions" can change quickly.
I'm very pleased with how $AVXL has been very prudent with the issuance of equity upon the best terms available to a microcap. Heck even the LPC deal was OK for the stage the company was at, at the time.
Wise CEO's raise funds via equity only when needed and market conditions are acceptable.
Funds are NOT currently needed nor are conditions good for equity financing.
AFTER successful P2b/3 results would be the most "prudent" time to raise funds.
Blarcamesine tweaks on these do-hickies inside the cells and restores function lost due to aging or genetic causes.
Basic enough?
A bad biz model is a bad biz model regardless of the specific challenges of the cannabis industry that make the sector extra difficult to navigate successfully.
Apparently $UNRV stores and sales are a ghost town too ... "This was a decrease of $9.29 million or 46.3% in revenue from continuing operations."
https://ir.unrivaledbrands.com/news-events/press-releases/detail/343/unrivaled-brands-reports-third-quarter-2022-financial
The Company realized an operating loss from continuing operations of $122.80 million for the three months ended September 30, 2022 compared to $11.70 million for the three months ended September 30, 2021, an increase of $111.10 million or 949.5%.
TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY=(42,111).
The equity is worthless.
If the agenda is to bash and spread FUD and there is no recent negative news, well yes, I'm sure some think the fact $AVXL was formed by reverse merger and traded OTC is relevant. Regardless of the fact $AVXL has ascended to top tier NASDAQ.
Anavex has an interesting history and as such an interesting shareholder base.
The driving force will soon be liquidity regardless of the reason.
What up with the use of the NASDAQ cross for a majority of the volume for such a long time? That's something that started happening after I retired. Open and close were always high volume, but $AVXL is seems excessive, but what do I know about how the internals work anymore?!?
but hey at least the brokers keep their funds segregated! Unlike FTX
Yes, I said...the institutional ownership grew in chunks not really the adjective of "gradual" and directly correspond to capital raises.
Yea the shitty institutions might be affected.
In my opinion, the institutional ownership grew in chunks not really the adjective of "gradual" and directly correspond to capital raises.
I absolutely disagree as if you look at a chart of institutional ownership since 2017 until today it shows continuous growth, thus continuous it relative to the timeframe.
Also if you dig deeper into the reports over time, you can see the number of smaller firms and "quality" of firms has also increased beyond just the indexes.
Do you agree?
Yes institutions use leverage, however this was in reference to retail brokerages changing margin requirements.
But, funny and correct commentary as I did margin calls. LOL